Rapid Fire presentation abstracts

Background: Over 10,000 Australian patients are prescribed Fluoropyrimidine (FP) chemotherapy annually for colorectal, gastrointestinal, breast and head and neck cancers. Severe toxicity, hospitalisation and death can result from dihydropyrimidine dehydrogenase (DPD) deficiency, the critical enzyme involved in FP metabolism. Genotyping of DPYD, the gene encoding DPD, can identify patients who carry variants for DPD deficiency (c.1905+1G>A, c.2846A>T, c.1679T>G and c.1236G>A) ahead of treatment to allow dose adjustments in order to improve FP tolerability.